{
  "source": "PA-Notification-Hemlibra.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1240-8\nProgram Prior Authorization/Notification\nMedication Hemlibra® (emicizumab-kxwh)\nP&T Approval Date 2/2018, 11/2018, 11/2019, 11/2020, 11/2021, 11/2022, 11/2023,\n11/2024\nEffective Date 2/1/2025\n1. Background:\nHemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody indicated\nfor routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and\npediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency)\nwith or without factor VIII inhibitors.\n2. Coverage Criteriaa:\nA. Hemophilia A\n1. Initial Authorization\na. Hemlibra will be approved based on both of the following criteria\n(1) Diagnosis of hemophilia A\n-AND-\n(2) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Hemlibra therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Medical Necessity may be in place\n© 2024 UnitedHealthcare Services Inc.\n1\n4. References:\n1. Hemlibra® [package insert]. South San Francisco, CA: Genentech, Inc.; January 2024.\nProgram Prior Authorization/Notification - Hemlibra (emicizumab-kxwh)\nChange Control\n2/2018 New program\n11/2018 Updated program to align with new labeled indication in patients with\nhemophilia A without inhibitors. Updated references.\n11/2019 Annu",
    "ibra (emicizumab-kxwh)\nChange Control\n2/2018 New program\n11/2018 Updated program to align with new labeled indication in patients with\nhemophilia A without inhibitors. Updated references.\n11/2019 Annual review. No changes to clinical coverage criteria. Updated\nreference.\n11/2020 Annual review. Updated references.\n11/2021 Annual review with no changes to clinical coverage criteria. Updated\nreference.\n11/2022 Annual review with no changes to clinical coverage criteria. Updated\nreference and added state mandate footnote.\n11/2023 Annual review with no changes to clinical coverage criteria. Updated\nreference.\n11/2024 Annual review with no changes to clinical coverage criteria. Updated\nreference.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}